MedTrace Logo

Investigating Whether Digital Acceptance Commitment Therapy Can Improve Mental Health for Hong Kong Cancer Patients Suffering From Depressive and Anxiety Symptoms.

NCT05583851 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-19

No results posted yet for this study

Summary

The goal of this clinical trial is to validate the use of digital Acceptance and Commitment Therapy (Digi-ACT) in Hong Kong curative cancer patients with depressive and anxiety symptoms. The main questions it aims to answer are:

* Can Digi-ACT reduce depressive or anxiety symptoms?
* Can Digi-ACT improved health-related quality of life?
* Is Digi-ACT an acceptable and feasible intervention for users?
* What are the factors that influence the success of Digi-ACT?
* Can the video journals used in Digi-ACT predict depressive symptoms?

Intervention group participants will install the Digi-ACT mobile application and undergo a 3-4 week long intervention. They will have to fill out questionnaires at baseline, immediately after the intervention, and at three month follow up to measure depression and anxiety symptoms, health-related quality of life, acceptability of the intervention, and other process outcomes related to the intervention itself.

Researchers will compare the outcomes with a group of participants that undergo a 3-4 week long period where they navigate a similar mobile platform that gives bi-daily psychoeducational videos that also fill out the same clinical questionnaires at baseline, post-intervention, and at three month follow up.

Conditions

  • Depression, Anxiety
  • Quality of Life
  • Cancer

Interventions

DEVICE

Acceptance and Commitment Therapy

Smartphone app guided and manualized version of acceptance and commitment therapy.

OTHER

Psychoeducation Active Control

Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.

Sponsors & Collaborators

  • OnCare Hong Kong

    collaborator UNKNOWN

  • The University of Hong Kong

    collaborator OTHER

  • Hollo

    lead OTHER

Principal Investigators

  • Wendy Wing-lok Chan, MBBS · LKS Faculty of Medicine, HKU

  • Kevin Ka Ming Wong, MBBS · OnCare Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-05-01
Completion
2023-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05583851 on ClinicalTrials.gov